Aethlon Medical Inc (AEMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aethlon Medical Inc (AEMD) has a cash flow conversion efficiency ratio of 0.000x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.87 Million) by net assets ($6.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AEMD defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Aethlon Medical Inc - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Aethlon Medical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aethlon Medical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aethlon Medical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Braille Energy Systems Inc
V:BES
|
-0.049x |
|
Dart Mining NL
AU:DTM
|
-0.035x |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
0.073x |
|
Kontrol Energy Corp
NEO:KNR
|
-0.005x |
|
Superior Industries International
NYSE:SUP
|
0.139x |
|
Supply@Me Capital PLC
LSE:SYME
|
0.084x |
|
Barbara Bui SA
PA:BUI
|
-0.698x |
|
AdvancedAdvT Ltd
LSE:ADVT
|
0.087x |
Annual Cash Flow Conversion Efficiency for Aethlon Medical Inc (1997–2025)
The table below shows the annual cash flow conversion efficiency of Aethlon Medical Inc from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see AEMD company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.12 Million | $-7.65 Million | -1.492x | +15.06% |
| 2024-03-31 | $5.77 Million | $-10.13 Million | -1.757x | -151.91% |
| 2023-03-31 | $15.06 Million | $-10.51 Million | -0.697x | -21.32% |
| 2022-03-31 | $16.99 Million | $-9.77 Million | -0.575x | +21.03% |
| 2021-03-31 | $9.29 Million | $-6.76 Million | -0.728x | -29.93% |
| 2020-03-31 | $9.28 Million | $-5.20 Million | -0.560x | +70.00% |
| 2019-03-31 | $2.30 Million | $-4.29 Million | -1.867x | -188.08% |
| 2018-03-31 | $6.03 Million | $-3.91 Million | -0.648x | +88.99% |
| 2017-03-31 | $595.41K | $-3.51 Million | -5.888x | -104.33% |
| 2016-03-31 | $1.50 Million | $-4.33 Million | -2.882x | +62.83% |
| 2015-03-31 | $651.38K | $-5.05 Million | -7.752x | -5438.35% |
| 2014-03-31 | $-14.73 Million | $-2.14 Million | 0.145x | -36.73% |
| 2013-03-31 | $-9.14 Million | $-2.10 Million | 0.230x | +15.87% |
| 2012-03-31 | $-9.30 Million | $-1.84 Million | 0.198x | -39.86% |
| 2011-03-31 | $-5.98 Million | $-1.97 Million | 0.329x | -26.67% |
| 2010-03-31 | $-4.40 Million | $-1.98 Million | 0.449x | -0.19% |
| 2009-03-31 | $-3.95 Million | $-1.78 Million | 0.450x | -28.95% |
| 2008-03-31 | $-3.32 Million | $-2.10 Million | 0.633x | +161.32% |
| 2007-03-31 | $-7.09 Million | $-1.72 Million | 0.242x | -73.08% |
| 2006-03-31 | $-1.76 Million | $-1.58 Million | 0.900x | +77.10% |
| 2005-03-31 | $-3.07 Million | $-1.56 Million | 0.508x | +242.85% |
| 2004-03-31 | $-3.66 Million | $-542.06K | 0.148x | +4.50% |
| 2003-03-31 | $-3.63 Million | $-514.50K | 0.142x | -69.05% |
| 2002-03-31 | $-2.20 Million | $-1.01 Million | 0.458x | +41.19% |
| 2001-03-31 | $-2.47 Million | $-800.67K | 0.325x | -65.90% |
| 2000-03-31 | $-713.05K | $-678.93K | 0.952x | +446.46% |
| 1999-03-31 | $-704.50K | $-122.75K | 0.174x | -88.46% |
| 1998-03-31 | $-1.23K | $-1.85K | 1.510x | +261.57% |
| 1997-03-31 | $2.37K | $-2.22K | -0.935x | -- |
About Aethlon Medical Inc
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Di… Read more